Fosfomycin-induced agranulocytosis: a case report and review of the literature.
Adverse drug reaction
Agranulocytosis
Drug safety
Fosfomycin
Neutropenia
leucopenia
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
13 Oct 2023
13 Oct 2023
Historique:
received:
10
01
2023
accepted:
26
09
2023
medline:
1
11
2023
pubmed:
14
10
2023
entrez:
13
10
2023
Statut:
epublish
Résumé
The intravenous form of fosfomycin, a bactericide antibiotic used to treat multiresistant bacterial infections is little prescribed. The most common reported adverse effects are hypokaliemia and hypernatremia. We describe a case of agranulocytosis, a rarely described side effect that may be fatal. A 45 year-old woman was admitted to the intensive care unit for post-surgical meningitis following meningioma resection. Meropenem and vancomycin were first introduced. A DRESS-syndrom with meropenem was suspected. Neutropenia was diagnosed three days after the introduction of parenteral fosfomycin and agranulocytosis four days later. Eosinophilia was also observed. A bone marrow aspiration was performed showing a disappearance of the neutrophil granulocyte line and a significant eosinophilia. Meropenem was discontinued. Fosfomycin was maintained and filgrastim was added. As filgrastim had no effect, the relationship with fosfomycin was suspected, so it was then withheld. An increase of the neutrophil count was observed. Because of the complexity of the case, the unfavorable course of the illness and the urgent need for revision surgery, a rechallenge with fosfomycin was done followed by a decrease of the neutrophil count. This is the third paper reporting agranulocytosis induced by fosfomycin, and the first detailed description of a case. Based on chronological and semiological criteria and bibliographic data, the event was qualified as probable with the Naranjo adverse drug probability scale. Literature data is scarce. The summary of product characteristics mentions that only a few cases of transient neutropenia and agranulocytosis have been reported. An analysis of the FDA Adverse Event Reporting System Database highlighted a higher than expected frequency of agranulocytosis in patients treated with fosfomycin. Parenteral fosfomycin is often used in patients receiving other medications, so that it is rarely the only suspect. In our case, the results of the bone marrow aspiration, the sudden drop of the neutrophil count with concomitant eosinophilia and the absence of improvement despite the dose decrease, point towards an immuno-allergic mechanism. However, the overlap between the suspected DRESS induced by meropenem and the agranulocytosis do not allow to conclude with certainty on the causality. Awareness should be raised about this side effect.
Sections du résumé
BACKGROUND
BACKGROUND
The intravenous form of fosfomycin, a bactericide antibiotic used to treat multiresistant bacterial infections is little prescribed. The most common reported adverse effects are hypokaliemia and hypernatremia. We describe a case of agranulocytosis, a rarely described side effect that may be fatal.
CASE PRESENTATION
METHODS
A 45 year-old woman was admitted to the intensive care unit for post-surgical meningitis following meningioma resection. Meropenem and vancomycin were first introduced. A DRESS-syndrom with meropenem was suspected. Neutropenia was diagnosed three days after the introduction of parenteral fosfomycin and agranulocytosis four days later. Eosinophilia was also observed. A bone marrow aspiration was performed showing a disappearance of the neutrophil granulocyte line and a significant eosinophilia. Meropenem was discontinued. Fosfomycin was maintained and filgrastim was added. As filgrastim had no effect, the relationship with fosfomycin was suspected, so it was then withheld. An increase of the neutrophil count was observed. Because of the complexity of the case, the unfavorable course of the illness and the urgent need for revision surgery, a rechallenge with fosfomycin was done followed by a decrease of the neutrophil count.
CONCLUSION
CONCLUSIONS
This is the third paper reporting agranulocytosis induced by fosfomycin, and the first detailed description of a case. Based on chronological and semiological criteria and bibliographic data, the event was qualified as probable with the Naranjo adverse drug probability scale. Literature data is scarce. The summary of product characteristics mentions that only a few cases of transient neutropenia and agranulocytosis have been reported. An analysis of the FDA Adverse Event Reporting System Database highlighted a higher than expected frequency of agranulocytosis in patients treated with fosfomycin. Parenteral fosfomycin is often used in patients receiving other medications, so that it is rarely the only suspect. In our case, the results of the bone marrow aspiration, the sudden drop of the neutrophil count with concomitant eosinophilia and the absence of improvement despite the dose decrease, point towards an immuno-allergic mechanism. However, the overlap between the suspected DRESS induced by meropenem and the agranulocytosis do not allow to conclude with certainty on the causality. Awareness should be raised about this side effect.
Identifiants
pubmed: 37833638
doi: 10.1186/s12879-023-08652-8
pii: 10.1186/s12879-023-08652-8
pmc: PMC10576332
doi:
Substances chimiques
Fosfomycin
2N81MY12TE
Filgrastim
PVI5M0M1GW
Meropenem
FV9J3JU8B1
Anti-Bacterial Agents
0
Types de publication
Review
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
685Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science. 1969;166(3901):122–3.
doi: 10.1126/science.166.3901.122
pubmed: 5809587
Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732–739.
doi: 10.1016/j.ijid.2011.07.007
pubmed: 21945848
De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-Approved compound Library identifies four small-molecule inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture. Antimicrob Agents Chemother. 2014;58(8):4875–84.
doi: 10.1128/AAC.03011-14
pubmed: 24841269
pmcid: 4136071
Iarikov D, Wassel R, Farley J, Nambiar S. Adverse events Associated with Fosfomycin Use: review of the literature and analyses of the FDA adverse event reporting System Database. Infect Dis Ther. 2015;4(4):433–58.
doi: 10.1007/s40121-015-0092-8
pubmed: 26437630
pmcid: 4675770
Vial T, Pofilet C, Pham E, Payen C, Evreux JC. [Acute drug-induced agranulocytosis: experience of the Regional Center of Pharmacovigilance of Lyon over 7 years]. Therapie. 1996;51(5):508–15.
pubmed: 9138385
Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017;23(6):363–72.
doi: 10.1016/j.cmi.2016.12.005
pubmed: 27956267
Portier H, Tremeaux JC, Chavanet P, Gouyon JB, Duez JM, Kazmierczak A. Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination. J Antimicrob Chemother. 1984;14(Suppl B):277–84.
doi: 10.1093/jac/14.suppl_B.277
pubmed: 6094452
Corti N, Sennhauser FH, Stauffer UG, Nadal D. Fosfomycin for the initial treatment of acute haematogenous osteomyelitis. Arch Dis Child. 2003;88(6):512–6.
doi: 10.1136/adc.88.6.512
pubmed: 12765918
pmcid: 1763134
Summary of product. characteristics – FOSFOMYCIN PANPHARMA 4 g, powder for solution for injection – French public drug database. Available on: https://base-donnees-publique.medicaments.gouv.fr/affichageDocphp?specid=63322018&typedoc=R#RcpEffetsIndesirables .